As businesses crank up their engines at the start of a new year, the economic landscape appears to carry a hope of recovery and rejuvenation - albeit a cautious one. Many have emerged from the tumult of last year's meltdown, wiser and better prepared for the challenges ahead.
In this issue of PharmaAsia, we feature a special Industry Outlook segment where industry leaders share their views on what to expect in 2010.
Perhaps symbolic of a new beginning, following the recent merger between Integra Biosciences and Viaflo Corporation, the companies have adopted the corporate brand - Integra, starting January 1.
China-based Hard to Treat Diseases (HTDS) has recently passed its "First Drug Evaluation" by the State Food and Drug Administration (SFDA), for the former's MMR (Measles, Mumps and Rubella) combined vaccine. The company estimates the market size in China to be 60 million doses per year.
As a testament to greater cooperation in the pharma playing field, Qiagen Asia Pacific and WuXi AppTec have commenced a partnership in Shanghai to provide an integrated single solution. The partnership is for molecular biomarker development, validation and personalized healthcare targets for the companies' respective client bases.
India-based Ranbaxy - a heavyweight in the generics market - has kicked off the year with a promising start as well. The company has launched a New Chemical Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology market. This milestone follows an in-licensing agreement with Japan's Summit Pharmaceuticals International, giving the former exclusive marketing rights in India.
At the international level, GlobalData has forecasted the Acute Ischemic Stroke (AIS) market to expand at a Compound Annual Growth Rate (CAGR) of 3.4 percent. According to the report, this historically static market offers potential for a pharmaceutical manufacturer whose drug can meet the needs of the market - if it can overcome existing product weaknesses and major adverse effects such as Intracranial Hemorrhage (ICH).
This is perhaps reflective of the competitive world that we live in, where opportunities for growth can be capitalized on - after one manages to rise above current circumstances and prevail over obstacles that stand in the way.
As things return to near normality, the survivors of 2009 can look forward to a fruitful year, equipped with lessons from the past - and a tenacity for success.
Del.icio.us |
